To the Editor In their Viewpoint1 about integrated drug reviews at the US Food and Drug Administration (FDA), Herder and colleagues1 noted that “in our view, integrated reviews are unlikely to achieve the agency’s stated goals and likely to introduce new problems,” referring to the goals of enhanced clarity of premarketing benefit–risk assessments and improved communication concerning approval decisions. The authors expressed concerns that there would be a loss of individual discipline reviews and dissenting viewpoints. The integrated reviews are part of the agency’s modernization initiative.2 The development process for the reviews included receipt and consideration of public comments from diverse stakeholders following a posting at Regulations.gov.3 In this Letter, we describe the purpose of integrated reviews and our assessment that they do not “circumvent [the FDA’s] legal obligation to prepare and publicly disclose individual scientific reviews.”1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Woodcock J, Stein P, Bugin K. Integrated Drug Reviews at the US Food and Drug Administration. JAMA Intern Med. 2020;180(9):1248–1250. doi:10.1001/jamainternmed.2020.1981
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: